TVRD — Tvardi Therapeutics Balance Sheet
0.000.00%
- $41.37m
- $4.91m
- $7.14m
- 27
- 19
- 27
- 12
Annual balance sheet for Tvardi Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 181 | 167 | 145 | 101 | 37.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.06 | 1.15 | 4.45 | 4.02 | 4.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 195 | 173 | 169 | 116 | 43.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.12 | 3.6 | 1.98 | 8.19 | 0 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 271 | 247 | 182 | 126 | 43.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.5 | 17.6 | 23.5 | 25.6 | 3.97 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 22.2 | 19.5 | 23.5 | 68.8 | 48.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 249 | 228 | 159 | 57.1 | -4.59 |
| Total Liabilities & Shareholders' Equity | 271 | 247 | 182 | 126 | 43.8 |
| Total Common Shares Outstanding |